Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL Study - Adults
NCT00480610Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2004
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of Tacrolimus Ointment 0.1% Iwaki in atopic dermatitis (AD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Number of exacerbations of atopic dermatitis requiring intervention at 12 months. Started Apr 2004; status: completed.
02
Drugs
Tacrolimus Ointment 0.1% Iwaki
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00480610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480610.